
CJC-1295 No DAC 10mg spray (also known as Modified GRF 1-29 or Mod GRF 1-29) is a research-grade synthetic GHRH analog formulated in a pre-metered liquid vehicle for non-invasive laboratory research. As a tetrasubstituted 29-amino-acid peptide, it targets GHRH receptors on pituitary somatotrophs to stimulate pulsatile growth hormone secretion. Formulated as a stabilized solution without Drug Affinity Complex (DAC), each bottle contains 10mg total active peptide, analytically verified by HPLC to support reproducible scientific investigations in endocrinology and mucosal transport kinetics.
HPLC certified
Independent analysis
Highest standard
Full traceability
CJC-1295 No DAC 10mg spray is a synthetic peptide solution containing a modified 29-amino-acid fragment of growth hormone-releasing hormone. Featuring four amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) to prevent rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-IV), this analog isolates pulsatile GHRH receptor activation. The 'No DAC' designation confirms the absence of the maleimidopropionic acid linker, preserving a short physiological half-life and preventing the continuous, non-pulsatile receptor stimulation associated with DAC-conjugated variants.
Researchers continue to investigate CJC-1295 No DAC across peptide pharmacology, endocrine regulation, and non-parenteral delivery systems. Its selective agonist action on pituitary GHRH receptors enables the study of endogenous somatotroph secretion kinetics and downstream IGF-1 feedback loops under controlled laboratory conditions. Formulated as a liquid spray, this product provides a pre-dissolved, concentration-verified format that bypasses reconstruction steps, making it a valuable molecular tool for laboratories examining mucosal barrier transport and olfactory uptake pathways.
CJC-1295 No DAC 10mg spray is a research-grade synthetic peptide solution developed for laboratory investigations involving growth hormone regulation, pituitary receptor signaling, and non-invasive delivery methods. Chemically classified as a modified GHRH(1-29) analog, its sequence is derived from the functional amino-terminal domain of native growth hormone-releasing hormone. To enhance biological stability, it incorporates four specific amino acid substitutions: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. This tetrasubstituted design creates a molecular structure that is functionally distinct from native GHRH(1-29) (Sermorelin) and DAC-conjugated GJC-1295 variants.
From a molecular research perspective, CJC-1295 No DAC Spray provides a valuable model for investigating the dynamics of pulsatile endocrine release. Pituitary somatotrophs release growth hormone in specific, periodic pulses regulated by GHRH and somatostatin cross-talk. By utilizing the 'No DAC' format, which lacks the albumin-binding Drug Affinity Complex linker, researchers can evaluate GHRH receptor binding and pituitary clearance kinetics that mimic physiological pulsatility. This is important for endocrine studies trying to avoid receptor downregulation or desensitization.
Current laboratory investigations examine CJC-1295 No DAC's interaction with pituitary GHRH receptors. Binding of the peptide activates the G-protein coupled receptor pathway, stimulating cyclic adenosine monophosphate (cAMP) accumulation, adenylate cyclase activity, and subsequent protein kinase A (PKA) phosphorylation. These intracellular cascades trigger the synthesis and release of growth hormone from somatotropic cells, allowing researchers to study signal transduction pathways under controlled in vitro and in vivo conditions.
Beyond pituitary receptor mechanics, researchers use CJC-1295 No DAC to explore downstream somatotrophic axis regulation. Studies evaluate how growth hormone release stimulated by GHRH receptor agonists coordinates hepatic insulin-like growth factor 1 (IGF-1) synthesis and release. This feedback loop is studied to analyze receptor sensitivity, cellular signaling thresholds, and homeostatic endocrine feedback mechanisms in preclinical models.
The liquid spray formulation provides an optimized experimental vehicle for investigating non-invasive mucosal epithelial transport. Researchers analyze how the modified 29-amino-acid peptide crosses nasal or oral mucosal barriers, evaluating tight junction interactions and trans-epithelial transport rates. Additionally, in neurobiology, the intranasal spray format is investigated to study direct olfactory transport pathways bypass of the blood-brain barrier for CNS-somatotrophic axis studies.
Each bottle of CJC-1295 No DAC 10mg spray is manufactured using solid-phase peptide synthesis (SPPS), followed by purification steps to isolate the high-purity tetrasubstituted peptide. The peptide is then dissolved in a stabilized, buffered aqueous solution calibrated to ensure exact concentration per metered spray activation. Quality control protocols include reverse-phase high-performance liquid chromatography (HPLC) for purity verification and liquid chromatography-mass spectrometry (LC-MS) for molecular identity confirmation.
To preserve the stability of the peptide in solution, CJC-1295 No DAC Spray should be stored under refrigeration (2°C to 8°C) and protected from light. Because GHRH analogs can undergo oxidation or deamidation in aqueous environments over time, maintaining refrigerated storage and minimizing atmospheric exposure is critical to preserving peptide integrity. Proper handling supports consistent concentration and analytical reproducibility across laboratory protocols.
Scientific interest in CJC-1295 No DAC continues to expand as researchers seek to characterize its stability, receptor interactions, and transport kinetics. Nevertheless, many aspects of its cellular signaling and epithelial transport remain active areas of scientific inquiry. Ongoing studies continue to refine the understanding of GHRH analog behavior in biological systems. For this reason, CJC-1295 No DAC 10mg spray should be regarded as an investigational compound whose primary value lies in advancing scientific knowledge of somatotropic receptor biology.
CJC-1295 No DAC 10mg spray is supplied exclusively for laboratory research and analytical applications. It is intended for Research Use Only (RUO) and is not approved for human consumption, therapeutic use, veterinary use, or diagnostic purposes.

Telomerase enzyme explained: how TERT and TERC maintain telomeres, why it matters in aging and cancer research, plus RUO peptide sourcing. Read the guide.

KLOW peptide research blend is drawing attention across California's research community. Discover its composition, COA basics, and current evidence limits.

Learn what a peptide bond is, how it forms through dehydration synthesis, and why its structure matters for research peptides. Read the full guide now.
(faqs)